About Rhythm Al, Ltd
Rhythm AI, Ltd. is a medical technology company specializing in advanced cardiac mapping solutions for the treatment of atrial fibrillation (AF). The company's flagship product, the STAR Apollo Mapping System, leverages sophisticated artificial intelligence algorithms rooted in fundamental electrophysiological principles to transform how physicians diagnose and treat AF. The system integrates seamlessly with existing electrophysiology (EP) systems to provide cutting-edge, real-time data analysis that uncovers repetitive patterns of activation (RPAs) and identifies early sites of activation (ESAs) that are potential drivers of atrial fibrillation. This breakthrough capability empowers cardiologists and electrophysiologists to develop highly personalized treatment plans tailored to each patient's unique cardiac rhythm patterns. By focusing on understanding the underlying rhythm complexity, STAR Apollo enables physicians to create individual treatment strategies that go beyond traditional approaches. The system has received FDA clearance and is designed to integrate easily into current clinical workflows, allowing healthcare providers to enhance their AF ablation procedures without disrupting established practices. Rhythm AI's technology represents a significant advancement in cardiac electrophysiology, combining artificial intelligence with deep clinical expertise to improve outcomes for patients suffering from atrial fibrillation.
Mission & Story
Mission
Navigating the Complexity of Atrial Fibrillation
Founding Story
Founded by Dr. Malcolm Finlay, a Consultant Cardiologist at Barts Heart Centre specializing in Cardiac Electrophysiology, who holds Honorary positions at QMUL and UCL developing minimally invasive technologies. His device innovation work is supported by the Barts NIHR Biomedical Research Centre.
Clinical Focus
Medical conditions and clinical areas addressed by Rhythm Al, Ltd.
Who It Serves
Milestones & Awards
Recent Milestones
FDA clearance for commercial release version of STAR Apollo Mapping System. FDA clearance for updated system with CARTO 3 compatibility. Appointment of Mike Dineen as CEO. Live case demonstrations at AF Symposium 2026 and RIO Congress.
Key Partnerships
Social & Media
Follow on
Latest Updates
RHYTHM AI announces FDA clearance for new STAR Apollo™ Mapping System
RHYTHM AI announces FDA clearance of the commercial release version of STAR Apollo™ Mapping System
FDA clears RHYTHM AI’s new algorithm for atrial fibrillation
RHYTHM AI announces new STAR Apollo™ Mapping System to feature at Rhythm Interventions Online (RIO) Congress
RHYTHM AI’s STAR Apollo™ Mapping System to feature in live case transmission at AF Symposium 2026
Company Details
- Employees
- 1-10
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingOfficial Sources
Similar Companies in this Market
View all 64 →
AccurKardia
AI-powered platform for cardiovascular disease detection and cardiac risk assessment.
Acorai
AI platform for cardiovascular disease detection and cardiac risk assessment.
Aisap
11-50 employees
AISAP provides FDA-cleared AI-powered diagnostic algorithms embedded in an operating system for point-of-care ultrasound (POCUS) devices. The platform enables rapid, expert-level cardiac imaging interpretation at the bedside, helping physicians detect structural heart disease early and make faster clinical decisions across hospitals, clinics, and screening programs.
AliveCor
AliveCor develops FDA-cleared, AI-powered ECG devices and software platforms for cardiac monitoring. The company offers portable ECG solutions ranging from consumer personal devices to clinical-grade 12-lead systems, serving patients, healthcare providers, biopharma companies, and health systems with remote and connected cardiac care.
Anumana AI
series c · 175 employees
Anumana AI develops and delivers AI-driven ECG algorithms to enable early diagnosis and intervention for cardiovascular conditions.
Artrya
11-50 employees
Artrya develops AI-powered solutions for rapid assessment of chest pain patients in emergency and primary care settings. The company's technology analyzes coronary computed tomography angiography (CCTA) to detect arterial plaque and stratify patient risk within minutes.
Bay Labs
Bay Labs is a health AI company focused on cardiology and cardiovascular health. The company's website is currently under construction with limited public information available.
BunkerHill Health
Bunkerhill Health provides Carebricks, an AI-powered platform that enables health systems to design, deploy, and operationalize AI agents across clinical and operational workflows. The platform reasons across patient data and automates actions within existing EHR systems.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.